{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:46:48Z","timestamp":1792597608747,"version":"4.5.0"},"reference-count":37,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"\n Importance<\/jats:title>\n Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis characterized by sterile ulcerative skin lesions. Multiple comorbidities and clinical features have been associated with PG, but no standardized guidelines exist for classifying PG phenotypes.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To develop an expert-established classification framework for PG phenotypes to inform treatment guidelines and future research endeavors.<\/jats:p>\n <\/jats:sec>\n \n Evidence Review<\/jats:title>\n In this modified Delphi consensus study that included 23 board-certified dermatologists and Medical Dermatology Society members with expertise in PG, panelists completed 5 rounds of anonymous, iterative online surveys that were administered from December 2023 through July 2025. Before the beginning of the consensus exercise, a literature review was performed by nonvoting researchers to summarize existing data on PG clinical associations and comorbidities. A PubMed search from inception to September 2023 identified observational studies, narrative reviews, systematic reviews, and meta-analyses describing PG clinical associations and comorbidities that were published in English. Experts indicated their agreement with proposed PG phenotypes and disease modifiers with a consensus threshold of 70% or greater. Anonymous comments and aggregated results were presented in each subsequent round. In the final round, a framework of PG phenotypes and disease modifiers was proposed for agreement.<\/jats:p>\n <\/jats:sec>\n \n Findings<\/jats:title>\n Twenty-three board-certified dermatologists and Medical Dermatology Society members with expertise in PG completed 5 rounds of iterative surveys. Consensus was reached on the final set of PG phenotypes and disease modifiers, with 83% of experts in agreement. PG phenotypes were overall classified into 2 major groups: PG with autoinflammatory syndromes and nonsyndromic PG. Nonsyndromic PG included 4 phenotypes: inflammatory bowel disease\u2013associated PG, PG in association with hematologic cancers and blood dyscrasias, drug-induced PG, and other (including idiopathic) PG. Disease modifiers of PG phenotype presentations included involvement of special sites (head\/neck, genitals, or peristomal skin) and extracutaneous manifestations.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This expert-established, descriptive framework provides a standardized classification system for distinct PG phenotypes and its modifiers. This nomenclature may inform upcoming clinical guidelines and allow for consistency in reporting epidemiological research and outcomes among patients with PG.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamadermatol.2026.2285","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T15:00:38Z","timestamp":1785942038000},"page":"1054","source":"Crossref","is-referenced-by-count":0,"title":["Pyoderma Gangrenosum Phenotype Classification"],"prefix":"10.1001","volume":"162","author":[{"given":"Ahana","family":"Gaurav","sequence":"first","affiliation":[{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Gregoire","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basil Alex","family":"McIntosh","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afsaneh","family":"Alavi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Bolognia","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Cowen","sequence":"additional","affiliation":[{"name":"Dermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo R.","family":"Dominguez","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Texas Southwestern Medical Center, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony P.","family":"Fernandez","sequence":"additional","affiliation":[{"name":"Departments of Dermatology and Pathology, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Fivenson","sequence":"additional","affiliation":[{"name":"Fivenson Dermatology, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Heffernan","sequence":"additional","affiliation":[{"name":"San Luis Dermatology and Laser Clinic, San Luis Obispo, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of North Carolina School of Medicine, Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Kaffenberger","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Ohio State University Wexner Medical Center, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Madigan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Utah Health, Salt Lake City"},{"name":"Images in Dermatology Editor, JAMA Dermatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Mauskar","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Texas Southwestern Medical Center, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander D.","family":"Means","sequence":"additional","affiliation":[{"name":"Dermatology Service Line, Advocate Aurora Healthcare, Oshkosh, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Nelson","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yale School of Medicine, New Haven, Connecticut"},{"name":"Assistant Section Editor, JAMA Dermatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Patsatsi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Aristotle University School of Medicine, Papageorgiou General Hospital, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Pugliese","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan W.","family":"Rojek","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California Irvine, Irvine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misha","family":"Rosenbach","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila","family":"Shaigany","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, Hempstead, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanade","family":"Shinkai","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California, San Francisco"},{"name":"Editor, JAMA Dermatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gideon","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Eastern Virginia Medical School, Norfolk"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Swerlick","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Emory School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Ortega-Loayza","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Oregon Health and Sciences University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Mostaghimi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"dcs260005r1","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.det.2023.08.003","article-title":"Pyoderma gangrenosum: diagnostic criteria, subtypes, systemic associations, and workup.","volume":"42","author":"Zaino","year":"2024","journal-title":"Dermatol Clin"},{"key":"dcs260005r2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2025.05.030","article-title":"Prevalence of pyoderma gangrenosum: a systematic review and meta-regression analysis.","author":"Shea","year":"2025","journal-title":"J Invest Dermatol"},{"issue":"3","key":"dcs260005r3","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/wrr.13005","article-title":"Pyoderma gangrenosum study pilot registry: The first step to a better understanding.","volume":"30","author":"Orfaly","year":"2022","journal-title":"Wound Repair Regen"},{"issue":"1","key":"dcs260005r4","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41572-020-0213-x","article-title":"Pyoderma gangrenosum.","volume":"6","author":"Maverakis","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"dcs260005r5","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1111\/iwj.13389","article-title":"Pyoderma gangrenosum: from historical perspectives to emerging investigations.","volume":"17","author":"Hobbs","year":"2020","journal-title":"Int Wound J"},{"issue":"4","key":"dcs260005r6","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1001\/jamadermatol.2017.5980","article-title":"Diagnostic criteria of ulcerative pyoderma gangrenosum: a Delphi consensus of international experts.","volume":"154","author":"Maverakis","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"4","key":"dcs260005r7","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1001\/jamadermatol.2017.5978","article-title":"The association of age with clinical presentation and comorbidities of pyoderma gangrenosum.","volume":"154","author":"Ashchyan","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"4","key":"dcs260005r8","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1159\/000519320","article-title":"Pyoderma gangrenosum and interleukin inhibitors: a semi-systematic review.","volume":"238","author":"Ben Abdallah","year":"2022","journal-title":"Dermatology"},{"issue":"2","key":"dcs260005r9","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/iwj.13067","article-title":"Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: a semi-systematic review.","volume":"16","author":"Ben Abdallah","year":"2019","journal-title":"Int Wound J"},{"issue":"2","key":"dcs260005r10","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.det.2023.12.002","article-title":"Treatment of Pyoderma Gangrenosum.","volume":"42","author":"Tan","year":"2024","journal-title":"Dermatol Clin"},{"issue":"4","key":"dcs260005r11","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s40257-018-0356-7","article-title":"Underlying systemic diseases in pyoderma gangrenosum: a systematic review and meta-analysis.","volume":"19","author":"Kridin","year":"2018","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"dcs260005r12","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1093\/bjd\/ljac137","article-title":"Features that define clinical severity of ulcerative pyoderma gangrenosum: a Delphi consensus study of experts and patients on behalf of the US Medical Dermatology Society.","volume":"188","author":"Pimentel","year":"2023","journal-title":"Br J Dermatol"},{"issue":"4","key":"dcs260005r13","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1046\/j.1365-2648.2000.t01-1-01567.x","article-title":"Research guidelines for the Delphi survey technique.","volume":"32","author":"Hasson","year":"2000","journal-title":"J Adv Nurs"},{"issue":"1","key":"dcs260005r14","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1001\/jamadermatol.2023.4450","article-title":"Management of adult patients with drug reaction with eosinophilia and systemic symptoms: a Delphi-based international consensus.","volume":"160","author":"Br\u00fcggen","year":"2024","journal-title":"JAMA Dermatol"},{"issue":"8","key":"dcs260005r15","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1001\/jamadermatol.2022.2044","article-title":"Isotretinoin laboratory monitoring in acne treatment: a Delphi consensus study.","volume":"158","author":"Xia","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"3","key":"dcs260005r16","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.abd.2024.07.014","article-title":"Pyoderma gangrenosum: a 22-year follow-up of patients in a tertiary reference hospital in Brazil.","volume":"100","author":"Salviano","year":"2025","journal-title":"An Bras Dermatol"},{"issue":"4","key":"dcs260005r17","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3776","article-title":"Pyoderma gangrenosum: a retrospective study of clinical characteristics, comorbidities, response to treatment and mortality related to prednisone dose.","volume":"101","author":"Sch\u00f8sler","year":"2021","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"dcs260005r18","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/bjd.16463","article-title":"Comorbidities of pyoderma gangrenosum: a retrospective multicentric analysis of 126 patients.","volume":"179","author":"Gillard","year":"2018","journal-title":"Br J Dermatol"},{"issue":"6","key":"dcs260005r19","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1111\/j.1365-2133.2011.10565.x","article-title":"Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients.","volume":"165","author":"Binus","year":"2011","journal-title":"Br J Dermatol"},{"issue":"6","key":"dcs260005r20","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s00403-019-01912-1","article-title":"Extracutaneous involvement of pyoderma gangrenosum.","volume":"311","author":"Borda","year":"2019","journal-title":"Arch Dermatol Res"},{"issue":"6","key":"dcs260005r21","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/j.jaad.2017.12.049","article-title":"Diagnosis and management of peristomal pyoderma gangrenosum: a systematic review.","volume":"78","author":"Afifi","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"dcs260005r22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.06.036","article-title":"Genetic basis of autoinflammatory skin diseases: part I: genetic pathways of complex autoinflammatory skin diseases.","author":"Burke","year":"2025","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"dcs260005r23","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.det.2023.12.004","article-title":"Hidradenitis suppurativa-related autoinflammatory syndromes: an updated review on the clinics, genetics, and treatment of pyoderma gangrenosum, acne and suppurative hidradenitis (PASH), pyogenic arthritis, pyoderma gangrenosum, acne and suppurative hidradenitis (PAPASH), synovitis, acne, pustulosis, hyperostosis and osteitis (SAPHO), and rarer forms.","volume":"42","author":"Maronese","year":"2024","journal-title":"Dermatol Clin"},{"issue":"9","key":"dcs260005r24","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1007\/s10620-019-05999-4","article-title":"Pyoderma gangrenosum in inflammatory bowel disease: a systematic review and meta-analysis.","volume":"65","author":"States","year":"2020","journal-title":"Dig Dis Sci"},{"key":"dcs260005r25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1234535","article-title":"Cutaneous manifestations of inflammatory bowel disease: basic characteristics, therapy, and potential pathophysiological associations.","volume":"14","author":"He","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"dcs260005r26","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00403-024-03689-4","article-title":"Anti-IL 17 biologics and pyoderma gangrenosum\u2014 therapeutic or causal?","volume":"317","author":"Wanzenberg","year":"2025","journal-title":"Arch Dermatol Res"},{"key":"dcs260005r27","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1124628","article-title":"IL-17 inhibitor-associated inflammatory bowel disease: a study based on literature and database analysis.","volume":"14","author":"Deng","year":"2023","journal-title":"Front Pharmacol"},{"key":"dcs260005r28","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1324258","article-title":"Neutrophilic and eosinophilic dermatoses associated with hematological malignancy.","volume":"10","author":"Maronese","year":"2024","journal-title":"Front Med (Lausanne)"},{"issue":"6","key":"dcs260005r29","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1007\/s00403-024-02958-6","article-title":"Janus kinase inhibitors in the treatment of pyoderma gangrenosum: case report and review.","volume":"316","author":"Gris\u00e9","year":"2024","journal-title":"Arch Dermatol Res"},{"issue":"6","key":"dcs260005r30","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1053\/j.jfas.2013.07.003","article-title":"Chronic leg ulceration associated with polycythemia vera responding to ruxolitinib (Jakafi).","volume":"52","author":"Shanmugam","year":"2013","journal-title":"J Foot Ankle Surg"},{"issue":"3","key":"dcs260005r31","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/cpt.70146","article-title":"Risk of malignancies and major adverse cardiovascular events related to JAK inhibitors in rheumatoid arthritis: a meta-analysis.","volume":"119","author":"Duan","year":"2026","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"dcs260005r32","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s40257-017-0308-7","article-title":"Drug-induced pyoderma gangrenosum: a review.","volume":"19","author":"Wang","year":"2018","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"dcs260005r33","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/bjd.15193","article-title":"Drug-induced pyoderma gangrenosum: a model to understand the pathogenesis of pyoderma gangrenosum.","volume":"177","author":"Wu","year":"2017","journal-title":"Br J Dermatol"},{"key":"dcs260005r34","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jdcr.2024.12.034","article-title":"Gilteritinib-induced pyoderma gangrenosum in a patient with acute myeloid leukemia: a case report.","volume":"58","author":"Sisley","year":"2025","journal-title":"JAAD Case Rep"},{"issue":"3","key":"dcs260005r35","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1111\/ajd.14221","article-title":"Understanding multi-kinase inhibitor-associated cutaneous ulcers may provide molecular insights into the aetiology of pyoderma gangrenosum: a comment on Jeon et al.","volume":"65","author":"Pham","year":"2024","journal-title":"Australas J Dermatol"},{"issue":"7","key":"dcs260005r36","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1093\/ced\/llaf104","article-title":"Pyoderma gangrenosum with extracutaneous involvement: a systematic review.","volume":"50","author":"Choe","year":"2025","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"dcs260005r37","doi-asserted-by":"publisher","DOI":"10.1111\/iwj.70334","article-title":"Clinical characteristics, treatments, and outcomes of pyoderma gangrenosum of the face: a systematic review.","volume":"22","author":"Kaur","year":"2025","journal-title":"Int Wound J"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2852249\/jamadermatology_gaurav_2026_cs_260005_1792511098.45641.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:00:44Z","timestamp":1792594844000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2852249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2026.2285","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,1]]}}}